TNFSF10 and glioblastoma: Exploiting the intrinsically higher TGF-β expression in glioblastoma than in normal brain tissue, some researchers have engineered human ASCs in order to increase the expression of TRAIL under the trigger of TGF-β signaling via a SMAD4-controlled minimal promoter [97].